DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage
- PMID: 8636997
- DOI: 10.1006/jmbi.1996.0274
DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage
Abstract
DNA gyrase, the bacterial enzyme that supercoils DNA, is trapped on chromosomal DNA by the 4-quinolone compounds, as drug-gyrase complexes that contain DNA breaks. Examination of chromosomal DNA extracted from Escherichia coli indicated that bacteriostatic concentrations of oxolinic acid trap gyrase and block DNA synthesis without releasing broken DNA from gyrase-DNA complexes. Release, detected as free rotation of DNA in the presence of an intercalating dye, occurred only at high, bactericidal oxolinic acid concentrations. Release of DNA breaks and cell death were both blocked by chloramphenicol, an inhibitor of protein synthesis, suggesting that synthesis of additional protein activity is required to free the DNA ends. Ciprofloxacin, a more potent quinolone, released DNA breaks and killed cells even in the presence of chloramphenicol. It is proposed that this second, chloramphenicol-insensitive mode for release of DNA breaks and cell killing arises from dissociation of gyrase subunits. Ciprofloxacin also killed a gyrase (gyrA) mutant resistant to the prototype of quinolone, nalidixic acid, and created complexes on DNA detected by DNA fragmentation. This lethal effect of ciprofloxacin was eliminated by additional mutations mapping in parC, one of the two genes encoding topoisomerase IV. Thus, the fluoroquinolone compounds have two intracellular targets. In the absence of the gyrA mutation, the parC (CipR) allele did not by itself confer resistance to ciprofloxacin, indicating that gyrase is the major quinolone target in E. coli. These findings provide a molecular explanation for quinolone action in bacteria and a new way to study topoisomerase IV-chromosome interactions.
Similar articles
-
gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.J Mol Biol. 2001 Jun 22;309(5):1219-31. doi: 10.1006/jmbi.2001.4733. J Mol Biol. 2001. PMID: 11399091
-
Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.Antimicrob Agents Chemother. 2001 Nov;45(11):3140-7. doi: 10.1128/AAC.45.11.3140-3147.2001. Antimicrob Agents Chemother. 2001. PMID: 11600369 Free PMC article.
-
Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.J Antimicrob Chemother. 2006 Dec;58(6):1283-6. doi: 10.1093/jac/dkl388. Epub 2006 Sep 26. J Antimicrob Chemother. 2006. PMID: 17003060
-
Mechanisms of action of and resistance to ciprofloxacin.Am J Med. 1987 Apr 27;82(4A):12-20. Am J Med. 1987. PMID: 3034057 Review.
-
Quinolone mode of action--new aspects.Drugs. 1993;45 Suppl 3:8-14. doi: 10.2165/00003495-199300453-00004. Drugs. 1993. PMID: 7689456 Review.
Cited by
-
Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.Int J Environ Res Public Health. 2015 May 13;12(5):5177-95. doi: 10.3390/ijerph120505177. Int J Environ Res Public Health. 2015. PMID: 25985315 Free PMC article.
-
Distribution of gyrase and topoisomerase IV on bacterial nucleoid: implications for nucleoid organization.Nucleic Acids Res. 2006 Jun 6;34(10):3128-38. doi: 10.1093/nar/gkl392. Print 2006. Nucleic Acids Res. 2006. PMID: 16757578 Free PMC article.
-
Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.Antimicrob Agents Chemother. 2001 Oct;45(10):2703-9. doi: 10.1128/AAC.45.10.2703-2709.2001. Antimicrob Agents Chemother. 2001. PMID: 11557458 Free PMC article.
-
Genome-wide mapping of fluoroquinolone-stabilized DNA gyrase cleavage sites displays drug specific effects that correlate with bacterial persistence.Nucleic Acids Res. 2023 Feb 22;51(3):1208-1228. doi: 10.1093/nar/gkac1223. Nucleic Acids Res. 2023. PMID: 36631985 Free PMC article.
-
Characterization of the Antibacterial Activity of Quinone-Based Compounds Originating from the Alnumycin Biosynthetic Gene Cluster of a Streptomyces Isolate.Antibiotics (Basel). 2023 Jun 28;12(7):1116. doi: 10.3390/antibiotics12071116. Antibiotics (Basel). 2023. PMID: 37508212 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources